Axon Ablation System
Phase 2- Indications
- Heart failure with preserved ejection fraction
Company intelligence / Profile preview
Axon Therapies has developed a minimally invasive, implant-free catheter-based procedure called Splanchnic Ablation for Volume Management (SAVM), targeting the greater splanchnic nerve to modulate sympathetic nervous system activity—a root cause of heart failure progression. Early clinical results from the REBALANCE-HF feasibility IDE trial show safety and efficacy signals, including improvements in pulmonary capillary wedge pressure during exercise and patient quality of life. Pilot studies demonstrated a durable effect at one year.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Axon Therapies.